TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9475269

Group type: EXPERIMENTAL
Intervention: molsidomine retard, 8 mg b.i.d.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: molsidomine, 4 mg t.i.d.
Number of subjects: 90
Study: 7609572

Group type: EXPERIMENTAL
Intervention: Continuous retrograde warm blood cardioplegia
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continuous retrograde mild hypothermic blood cardioplegia
Number of subjects: 21
Study: 2797640

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (3 doses of 1-g intravenous cefazolin before, during, and 6-8 hours after surgery)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 26
Study: 382158

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 5
Study: 30898520

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Number of subjects: 313

Group type: COMPARATOR
Intervention: High-flow oxygen therapy
Number of subjects: 313
Study: 30153753

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 27017776

Group type: EXPERIMENTAL
Intervention: Tegadarm comfort film dressing with aron alpha A [Sankyo] (TA group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tegadarm film (T group)
Number of subjects: 20
Study: 25147030

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 691

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 691
Study: 22984831

Group type: EXPERIMENTAL
Intervention: Changing the public behavior of a randomly assigned subset of student social referents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social referents' public behavior
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interaction shaped by institutional channels like shared classes
Number of subjects: 0
Study: 18625521

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 17575465

Group type: EXPERIMENTAL
Intervention: Combined program of aquatic exercise plus high-intensity strength training (group 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Combined program of aquatic exercise plus calisthenic training (group 2)
Number of subjects: 62
Study: 15379051

Group type: EXPERIMENTAL
Intervention: Verorab vaccine (3 intramuscular doses at days 0, 7, and 28)
Number of subjects: 54

Group type: COMPARATOR
Intervention: CRL vaccine (4 subcutaneous doses at days 0, 3, 7, and 28)
Number of subjects: 54
Study: 11803988

Group type: EXPERIMENTAL
Intervention: Battery-operated power toothbrush (Dr. Johns Spin Brush Classic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual toothbrush (ADA toothbrush)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual toothbrush (CrossAction toothbrush)
Number of subjects: 0
Study: 9580255

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b, 5 million units, subcutaneously daily for 16 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Prednisone for a total of six weeks prior to interferon starting at 60 mg daily with reduction in dosage by 20 mg every two weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b
Number of subjects: 23
Study: 7973768

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and radiation therapy followed by resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin plus vinorelbine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboplatin and vinorelbine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 0
Study: 3057852

Group type: EXPERIMENTAL
Intervention: Disopyramide 150 mg 4 times a day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol 40 mg 4 times a day
Number of subjects: 10
Study: 30842721

Group type: EXPERIMENTAL
Intervention: simBiCI group
Number of subjects: 38

Group type: COMPARATOR
Intervention: UCI/seqBiCI group
Number of subjects: 38
Study: 28428187

Group type: EXPERIMENTAL
Intervention: Direct distribution of HIV self-test (HIVST) from peer educator
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Fixed distribution of a coupon to collect HIVST from a drug store or health post
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard of care (referral to existing HIV testing services only, without any offer of HIVST)
Number of subjects: 900
Study: 25891173

Group type: EXPERIMENTAL
Intervention: Pembrolizumab every 2 weeks
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Pembrolizumab every 3 weeks
Number of subjects: 834

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 834
Study: 22782539

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg loading dose with dabigatran etexilate 150 mg bid (part 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose with dabigatran etexilate 150 mg bid (part 3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg qd with dabigatran etexilate 150 mg bid (part 2)
Number of subjects: 20
Study: 21496674

Group type: EXPERIMENTAL
Intervention: ZOE-based sealer with powder/liquid ratio of 1:2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ZOE-based sealer with powder/liquid ratio of 1:3
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gutta-percha alone (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ZOE-based sealer with powder/liquid ratio of 1:1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ZOE-based sealer with powder/liquid ratio of 1:4
Number of subjects: 50
Study: 18463543

Group type: EXPERIMENTAL
Intervention: Yoga therapy (surya namaskara, pranayama, avartan dhyan)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (simple physical exercises)
Number of subjects: 120
Study: 16129526

Group type: EXPERIMENTAL
Intervention: Intranasal proteosome‐adjuvanted vaccine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Intranasal saline
Number of subjects: 2
Study: 14498756

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 or 20 mg (on-demand, not more than once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16394324

Group type: COMPARATOR
Intervention: Bolus priming (10 microg/kg)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Priming infusion (5 microg/kg/min) for vecuronium (15 microg/kg)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Higher priming infusion (10 microg/kg/min) for vecuronium (15 microg/kg)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Priming infusion (10 microg/kg/min) for vecuronium (20 microg/kg)
Number of subjects: 112
Study: 10599981

Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study: 8609288

Group type: COMPARATOR
Intervention: Normal-hearing listeners
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hearing-impaired listeners
Number of subjects: 14
Study: 1783914

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg twice daily (n = 815)
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily (n = 806)
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Placebo (n = 814)
Number of subjects: 2435
Study: 7015129

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31409421

Group type: EXPERIMENTAL
Intervention: Oral HIV self-testing (HIVST) provided for eligible household members who are absent or decline testing.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care for absent and refusing individuals (referral to a health facility).
Number of subjects: 0
Study: 29275344

Group type: EXPERIMENTAL
Intervention: Standard of care plus a 12-week cardiovascular rehabilitation programme (60 min of education plus two 60 min aerobic exercise sessions/week at 60%-80% of heart rate reserve)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment
Number of subjects: 60
Study: 24954016

Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency (PRFT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard-voltage pulsed radiofrequency (PRFT)
Number of subjects: 60
Study: 24417760

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 43
Study: 22488613

Group type: EXPERIMENTAL
Intervention: Cemented Exeter implant
Number of subjects: 160

Group type: COMPARATOR
Intervention: Uncemented Zweymüller Alloclassic implant
Number of subjects: 160
Study: 19525856

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 18163098

Group type: EXPERIMENTAL
Intervention: Chronic apical periodontitis (CAP) involving not more than 2 teeth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic apical periodontitis (CAP) involving plural CAP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic inflammation course in periodontal tissues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protracted multiple infectious focuses in periodontal tissues
Number of subjects: 0
Study: 15198753

Group type: EXPERIMENTAL
Intervention: Intramuscular pethidine 100 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 50
Study: 11164124

Group type: EXPERIMENTAL
Intervention: Combined weight loss and sodium reduction
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Sodium reduction
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 900

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 900
Study: 9509973

Group type: EXPERIMENTAL
Intervention: BUCY (busulfan 16 mg/kg and cyclophosphamide 120 mg/kg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: BEAC (carmustine 300 mg/m2, etoposide 600 mg/m2, cytarabine 600 mg/m2, and cyclophosphamide 140 mg/kg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: BUCY
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: BEAC
Number of subjects: 49
Study: 7997351

Group type: EXPERIMENTAL
Intervention: Pneumatic gouge
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard method
Number of subjects: 50
Study: 31006069

Group type: EXPERIMENTAL
Intervention: MySpineTM 3D-printed patient-specific guides
Number of subjects: 29

Group type: COMPARATOR
Intervention: Free-hand implantation
Number of subjects: 29
Study: 28508515

Group type: EXPERIMENTAL
Intervention: Pre-hydrated collagenated cortico-cancellous porcine bone (coll-group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cortical porcine bone (cort-group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Naturally-healing group (nat-group)
Number of subjects: 55
Study: 26571488

Group type: EXPERIMENTAL
Intervention: Hypoallergenic formula supplemented with prebiotic galacto‐oligosaccharides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypoallergenic formula without supplementation (Control)
Number of subjects: 0
Study: 23639822

Group type: EXPERIMENTAL
Intervention: Motion style acupuncture treatment (MSAT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional diclofenac injection
Number of subjects: 58
Study: 21974834

Group type: EXPERIMENTAL
Intervention: Multi-professional medication review at baseline and 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (support from the National Health Service)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multi-professional medication review
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 18434573

Group type: EXPERIMENTAL
Intervention: Mandibular implant overdentures
Number of subjects: 173

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 173
Study: 16966504

Group type: EXPERIMENTAL
Intervention: Low-frequency STN DBS (10 Hz)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-frequency STN DBS (130 Hz)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 12
Study: 14531810

Group type: EXPERIMENTAL
Intervention: Loop diuretic (furosemide or torsemide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily loop diuretic administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 0
Study: 11005907

Group type: EXPERIMENTAL
Intervention: Smith‐Nephew's Skin‐Prep (SP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Secure(2) Medical Adhesive (SMA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epithane‐3 (E3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Uni‐Solve adhesive remover (US)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No SP
Number of subjects: 20
Study: 9013470

Group type: EXPERIMENTAL
Intervention: rHu GM-CSF (group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no rHu GM-CSF, group 2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (1 and 2)
Number of subjects: 28
Study: 8214465

Group type: EXPERIMENTAL
Intervention: All groups (ginger, metoclopramide, placebo)
Number of subjects: 120
Study: 3698464

Group type: EXPERIMENTAL
Intervention: Indomethacin (200 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29652758

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 54
Study: 27494448

Group type: EXPERIMENTAL
Intervention: LowCHO diet (Carb:Pro:Fat:Sat-Fat 14:28:58: < 10% energy; n=58)
Number of subjects: 115

Group type: COMPARATOR
Intervention: HighCHO diet (53:17:30: < 10%; n=57)
Number of subjects: 115
Study: 24602992

Group type: EXPERIMENTAL
Intervention: CBTp
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wait-list group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined sample (immediate CBTp + delayed CBTp)
Number of subjects: 80
Study: 22316334

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 g kg-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl 1 g kg-1
Number of subjects: 0
Study: 20128531

Group type: EXPERIMENTAL
Intervention: Ferrara intracorneal ring segments (ICRS) implantation
Number of subjects: 37
Study: 18254150

Group type: EXPERIMENTAL
Intervention: Levonorgestrel tablet formulation 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levonorgestrel tablet formulation 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (general)
Number of subjects: 0
Study: 15983467

Group type: COMPARATOR
Intervention: Intraoperative remifentanil at 0.40 microg x kg(‐1) x min(‐1) (large-dose remifentanil)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil at 0.05 microg x kg(‐1) x min(‐1) (small-dose remifentanil)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil at 0.40 microg x kg(‐1) x min(‐1) and 0.5 mg/kg ketamine just after induction (large-dose remifentanil-ketamine)
Number of subjects: 75
Study: 12208707

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1077
Study: 10624455

Group type: EXPERIMENTAL
Intervention: Pamidronate 150 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7575752

Group type: EXPERIMENTAL
Intervention: Indometacin 75 mg bid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indometacin 75 mg bid plus roxatidine acetate 75 mg nocte
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indometacin 75 mg bid plus roxatidine acetate 75 mg bid
Number of subjects: 12
Study: 1782227

Group type: EXPERIMENTAL
Intervention: UDCA (13‐15 mg/kg per day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 7052802

Group type: EXPERIMENTAL
Intervention: Group I (no visual reinforcement)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group II (with visual reinforcement)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group III (non-reinforced, 15 randomizations of List A at 16 db SL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group IV (non-reinforced, 15 randomizations of List A at 56 db SL)
Number of subjects: 20
Study: 30544141

Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Sleep paralysis frequency
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Dissociative experiences during wakefulness
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Nightmares
Number of subjects: 1882
Study: 30039165

Group type: EXPERIMENTAL
Intervention: Ultra-early neurological deterioration (U-END) in patients with intracranial hemorrhage
Number of subjects: 1690

Group type: EXPERIMENTAL
Intervention: Ultra-early neurological deterioration (U-END)
Number of subjects: 1690
Study: 27498334

Group type: EXPERIMENTAL
Intervention: CaO-SiO2-P2O5-B2O3 bioactive glass ceramics spacer
Number of subjects: 86

Group type: COMPARATOR
Intervention: Titanium cage
Number of subjects: 86
Study: 24603400

Group type: EXPERIMENTAL
Intervention: Breathing exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proton pump inhibitors
Number of subjects: 0
Study: 22650121

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Warming needle moxibustion (WNM)
Number of subjects: 74
Study: 20419154

Group type: EXPERIMENTAL
Intervention: Telaprevir (HCV protease inhibitor), specific dosage and duration not mentioned
Number of subjects: 0
Study: 18656299

Group type: EXPERIMENTAL
Intervention: S1 intensity
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: S1 variability
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ventricular pacing
Number of subjects: 57
Study: 16242473

Group type: EXPERIMENTAL
Intervention: Cervical lymph node dissection
Number of subjects: 30

Group type: COMPARATOR
Intervention: No cervical lymph node dissection
Number of subjects: 30
Study: 14636105

Group type: EXPERIMENTAL
Intervention: Vitamin E (VE) supplementation (1200 IU/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study: 10909992

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8878083

Group type: EXPERIMENTAL
Intervention: 20 g sorbitol and 20 g glucose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 20 g sorbitol and 9 g lipids
Number of subjects: 6

Group type: COMPARATOR
Intervention: 20 g sorbitol alone
Number of subjects: 6
Study: 1813715

Group type: EXPERIMENTAL
Intervention: Pseudomonas immunoglobulin (250 mg/kg) administered intravenously on days 3, 5, 7, 10, and 13 after trauma
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pseudomonas immunoglobulin (PIG-SUBGRP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CON-SUBGRP)
Number of subjects: 60
Study: 6390248

Group type: EXPERIMENTAL
Intervention: iohexol (Omnipaque)
Number of subjects: 50

Group type: COMPARATOR
Intervention: metrizamide (Amipaque)
Number of subjects: 50
Study: 31056697

Group type: EXPERIMENTAL
Intervention: Maternal influenza vaccination
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study: 28915853

Group type: EXPERIMENTAL
Intervention: CT-targeted touch (slow brushing)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heat-pain (HP) stimulation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CT-targeted touch combined with HP stimulation
Number of subjects: 40
Study: 26460306

Group type: EXPERIMENTAL
Intervention: Computerized cognitive intervention (25 training sessions at home with weekly coaching)
Number of subjects: 68
Study: 25325208

Group type: EXPERIMENTAL
Intervention: Moderate-dose non-liberal-interval dosage (MDNLD) regimen (12.5 mg/Kg every 12 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-dose extended-interval dosage (HDED) regimen (25 mg/Kg every 24 hours)
Number of subjects: 40
Study: 22888489

Group type: EXPERIMENTAL
Intervention: Merocel middle meatal spacer (MMMS)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Finger glove Merocel middle meatal spacer (FGMMS)
Number of subjects: 37
Study: 19254942

Group type: EXPERIMENTAL
Intervention: AC (doxorubicin 40 mg/m2 plus cyclophosphamide 500 mg/m2)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: D (single-agent docetaxel 60 mg/m2)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: AC-D (alternating regimen of AC and docetaxel)
Number of subjects: 441
Study: 17767753

Group type: EXPERIMENTAL
Intervention: Bixa Orellana (BO) 250 mg 3 times a day for 12 months
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (Pbo)
Number of subjects: 136
Study: 15162353

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise Training (PRET)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care intervention
Number of subjects: 20
Study: 10764302

Group type: COMPARATOR
Intervention: Tiotropium 0 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium 4.5 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium 9 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium 36 microg
Number of subjects: 0
Study: 8818066

Group type: EXPERIMENTAL
Intervention: Health-related physical education (P+) program
Number of subjects: 2096
Study: 1425545

Group type: EXPERIMENTAL
Intervention: Unsolicited, mailed, self-help smoking cessation program
Number of subjects: 1396

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1396
Study: 3988415

Group type: EXPERIMENTAL
Intervention: Potassium + Magnesium Aspartate (K + Mg Asp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 30998237

Group type: EXPERIMENTAL
Intervention: Growth Hormone (0.67 mg/m2/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30004039

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg once daily
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Tadalafil 5.0 mg once daily
Number of subjects: 635

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 635
Study: 27329023

Group type: EXPERIMENTAL
Intervention: Primary care screening
Number of subjects: 781

Group type: COMPARATOR
Intervention: Secondary care screening
Number of subjects: 781